Maven Securities LTD Sells 25,000 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX)

Maven Securities LTD decreased its stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 50.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,000 shares of the company's stock after selling 25,000 shares during the period. Maven Securities LTD's holdings in Bicara Therapeutics were worth $436,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of BCAX. Spire Wealth Management bought a new stake in shares of Bicara Therapeutics in the 4th quarter worth approximately $31,000. BNP Paribas Financial Markets acquired a new position in shares of Bicara Therapeutics during the 4th quarter valued at $32,000. Legal & General Group Plc acquired a new position in shares of Bicara Therapeutics during the 4th quarter valued at $33,000. Summit Investment Advisors Inc. acquired a new position in shares of Bicara Therapeutics during the 4th quarter valued at $35,000. Finally, Virtus ETF Advisers LLC acquired a new position in shares of Bicara Therapeutics in the 4th quarter worth $69,000.

Bicara Therapeutics Trading Up 3.1%

NASDAQ:BCAX traded up $0.46 during mid-day trading on Monday, hitting $14.93. The stock had a trading volume of 118,676 shares, compared to its average volume of 486,309. Bicara Therapeutics Inc. has a twelve month low of $8.91 and a twelve month high of $28.09. The company's 50 day simple moving average is $12.81 and its 200 day simple moving average is $15.20.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.28). Sell-side analysts forecast that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on BCAX. Stifel Nicolaus set a $48.00 target price on Bicara Therapeutics in a report on Thursday, March 27th. HC Wainwright decreased their target price on Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating for the company in a research report on Friday. Wedbush reaffirmed an "outperform" rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Wells Fargo & Company initiated coverage on Bicara Therapeutics in a research report on Thursday, April 17th. They issued an "underweight" rating and a $8.00 target price for the company. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $13.01 price objective on shares of Bicara Therapeutics in a report on Thursday, March 13th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $32.00.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.